Regulus Therapeutics Inc (NASDAQ:RGLS) Short Interest Up 50.4% in July

Regulus Therapeutics Inc (NASDAQ:RGLS) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 647,300 shares, an increase of 50.4% from the June 30th total of 430,500 shares. Based on an average daily trading volume, of 201,300 shares, the short-interest ratio is currently 3.2 days. Currently, 11.0% of the shares of the company are sold short.

RGLS has been the topic of several recent research reports. ValuEngine upgraded Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Wedbush restated a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Finally, Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Five equities research analysts have rated the stock with a hold rating, Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $1.25.

In related news, insider Joseph P. Hagan sold 39,352 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $1.22, for a total value of $48,009.44. Following the sale, the insider now owns 307,519 shares in the company, valued at $375,173.18. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 66,979 shares of company stock worth $85,896. 10.70% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. NEA Management Company LLC raised its stake in Regulus Therapeutics by 124.1% in the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock valued at $2,566,000 after purchasing an additional 1,136,704 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Regulus Therapeutics in the 1st quarter worth $68,000. Finally, Wedbush Securities Inc. increased its stake in shares of Regulus Therapeutics by 32.8% in the 1st quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,751 shares during the last quarter. 12.79% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:RGLS traded up $0.02 during midday trading on Monday, reaching $0.58. 78,800 shares of the company’s stock traded hands, compared to its average volume of 230,672. Regulus Therapeutics has a 1 year low of $0.50 and a 1 year high of $4.08. The stock has a market cap of $12.21 million, a P/E ratio of -0.10 and a beta of 1.90. The company has a fifty day simple moving average of $1.01.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.24. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 396.84%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $2.50 million. Research analysts anticipate that Regulus Therapeutics will post -2.13 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit